Rifaldin 300 mg cápsulas, Rimactán 300 mg cápsulas duras, Cemidón 300 B6, RIFAPENTINE
PI21/004444
Approved small_molecule active
Quick answer
Rifaldin 300 mg cápsulas, Rimactán 300 mg cápsulas duras, Cemidón 300 B6, RIFAPENTINE for Latent tuberculosis infection in patients with end-stage kidney disease. is a Approved program (small_molecule) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Latent tuberculosis infection in patients with end-stage kidney disease.
- Phase
- Approved
- Modality
- small_molecule
- Status
- active